Login to Your Account

GHIT injected with $200M in funding

By Kohei Kanayasu
Staff Writer

Wednesday, June 14, 2017

TOKYO – With $200 million in new funding, the Global Health Innovative Technology (GHIT) Fund is poised to continue funding early and midstage drug development projects for the next five years, particularly for neglected diseases that disproportionately affect developing markets.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription